The Neurolixis lead compound, NLX-112, is at the heart of a new brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, also known as befiradol or F13640, was radiolabeled and administered to healthy adults as part of an ongoing clinical study led by Prof. Luc Zimmer of the Cermep brain imaging center in Lyon, France.

The study shows that, unlike previous radiotracers, 18F-labeled NLX-112 binds to 5-HT1A receptors which are functionally-responsive, and shows accentuated labeling in specific cortical brain regions. The first data from the study were published as the 'Image of the month' in the 'European Journal of Nuclear Medicine and Molecular Imaging'. 

18F-F13640 PET imaging of functional receptors in humans
Colom M., Costes N., Redouté J., Dailler F., Gobert F., Le bars D., Billard T., Newman-Tancredi A., Zimmer L. 
Eur J Nucl Med Mol Imaging (2019).

Full Press Release Here.


Please enable the javascript to submit this form

Follow Neurolixis on: